MS Clinical Trials in Michigan

30 active trials · 13 recruiting

30 active multiple sclerosis clinical trials have at least one study site in Michigan, 13 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.

Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 8 MS treatment centers in Michigan; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.

Active MS trials with sites in Michigan

RecruitingPhase 3

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Sponsor: TG Therapeutics, Inc.

Ublituximab · Placebo

25 states800 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Sponsor: Novartis Pharmaceuticals

Remibrutinib oral treatment · Ocrelizumab

18 states360 participantsDetails ›

RecruitingPhase 3

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Sponsor: Amgen

Ocrelizumab (US) · Ocrelizumab (EU)

17 states444 participantsDetails ›

RecruitingPhase 3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Remibrutinib (blinded) · Placebo

10 states1275 participantsDetails ›

RecruitingPhase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Sponsor: National Cancer Institute (NCI)

Biospecimen Collection · Nivolumab

19 states300 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Teriflunomide

35 states1600 participantsDetails ›

Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Sponsor: TG Therapeutics, Inc.

No Intervention

29 states500 participantsDetails ›

RecruitingPhase 3

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Sponsor: Sanofi

Frexalimab · Placebo

38 states900 participantsDetails ›

RecruitingNA

Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients

Sponsor: University of Michigan

Virtual Reality · Standard care

1 state40 participantsDetails ›

RecruitingPhase 2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Sponsor: ModernaTX, Inc.

mRNA-1195 · Placebo

5 states180 participantsDetails ›

RecruitingNA

Promotion of Exercise Through Physical Therapy for Multiple Sclerosis: A Pilot Study

Sponsor: University of Michigan

PromPT-MS

1 state40 participantsDetails ›

RecruitingPhase 2

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

Sponsor: Tiffany J. Braley, MD, MS

Cannabidiol (CBD) · Tetrahydrocannabinol (THC)

1 state166 participantsDetails ›

Recruiting

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Sponsor: Wayne State University

Observation of Ocrelizumab as Treatme…

1 state80 participantsDetails ›

Closed to new patientsPhase 4

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Disease modifying treatment (DMT)

19 states136 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

16 states769 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Fenebrutinib · Ocrelizumab

24 states985 participantsDetails ›

Closed to new patientsPhase 3

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab

Sponsor: Novartis Pharmaceuticals

Ofatumumab approved dose · Ofatumumab new dose

24 states196 participantsDetails ›

Closed to new patientsPhase 3

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Sponsor: Novartis Pharmaceuticals

Remibrutinib · Teriflunomide

27 states1001 participantsDetails ›

Closed to new patientsPhase 3

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Sponsor: Novartis Pharmaceuticals

Ofatumumab · Tetanus toxoid (TT) containing vaccin…

32 states1882 participantsDetails ›

Closed to new patientsPhase 3

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Sponsor: TG Therapeutics, Inc.

Ublituximab

14 states1100 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Teriflunomide

23 states746 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Ocrelizumab · Ocrelizumab

20 states864 participantsDetails ›

Closed to new patientsPhase 3

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Sponsor: Sanofi

Tolebrutinib · Placebo

27 states2500 participantsDetails ›

Closed to new patientsPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

26 states1300 participantsDetails ›

Closed to new patientsPhase 3

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

13 states927 participantsDetails ›

Closed to new patientsNA

TRAIN-BW: Backward Walking Training in Multiple Sclerosis

Sponsor: Wayne State University

Backward Walking Training · Forward Walking Training

1 state90 participantsDetails ›

Closed to new patientsPhase 3

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Interferon beta-1a · Fingolimod

8 states240 participantsDetails ›

Closed to new patientsNA

Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Sponsor: Johns Hopkins University

Natalizumab/natalizumab-sztn, Alemtuz… · Glatiramer acetate, Interferons (intr…

28 states900 participantsDetails ›

Closed to new patients

Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)

Sponsor: University of Michigan

2 states300 participantsDetails ›

Closed to new patientsPhase 2

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Sponsor: Immunic AG

IMU-838 · Placebo matching IMU-838

6 states450 participantsDetails ›

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Active MS trials with sites in Michigan

MS trials in other states